Vaccinex, Inc.

FOR IMMEDIATE RELEASE

VACCINEX, INC. SELECTED TO PRESENT AT BIO 2002 INVESTOR FORUM

Rochester, N.Y. June 10, 2002 Vaccinex, Inc. is among a select number of biotechnology companies that will make presentations before an international audience of investors, journalists, and biotechnology and pharmaceutical insiders at BIO 2002, the major biotechnology industry trade show taking place in Toronto, June 9th-12th. Vaccinex will be presenting on June 11th at 2:45pm in the Toronto Convention Centre. Vaccinex will, in addition, be participating as an exhibiting company throughout the trade show.

Vaccinex was selected from an elite pool of more than 420 applicants to present at the BIO 2002 Business Forum. Companies selected to present at the Business Forum hail from Australia, Austria, Canada, Denmark, Finland, France, Germany, Israel, the Netherlands, Switzerland, the United Kingdom and the United States.

Maurice Zauderer, Ph.D., Vaccinex's President and CEO stated, "The participation and visibility of Vaccinex at this premier meeting of the biotechnology industry is a reflection of the progress the company has made in developing exciting new applications for its powerful gene discovery technology. Vaccinex has begun marketing its novel Human Monoclonal Antibody Selection Technology as a service to other biopharmaceutical companies and is, at the same time, preparing for clinical trials of its lead product, a therapeutic vaccine for breast cancer."

The 16th Annual BIO 2002 Convention & Exhibition is being held outside the United States for just the second time. More than 15,000 delegates from all over the world will participate in what will be the largest gathering ever for the biotechnology industry. BIO 2002 is sponsored by the Biotechnology Industry Organization (www.BIO.org), which is located in Washington, DC.

Headquartered in Rochester, NY, Vaccinex, Inc. is a privately owned biotechnology company developing treatments that harness the power of the body's immune system to fight cancer and other diseases. The company has developed a suite of powerful technologies to identify genes that regulate important biological processes. Vaccinex utilizes the knowledge derived from these technologies in the development of monoclonal antibody-based therapeutics and therapeutic vaccines. For more information, please visit the company's website at www.vaccinex.com.

Back to News Archive


About Us Executive Team Board of Directors Scientific/ Clinical Advisors Business Strategy Collabora- tions Antibody Technology Overview Membrane Antibody Expression and Selection Secreted IgG Antibody Selection Antibody Animation Development Strategy Development Pipeline


	FOR IMMEDIATE RELEASE VACCINEX, INC. SELECTED TO PRESENT AT BIO 2002 INVESTOR FORUM Rochester, N.Y. June 10, 2002 Vaccinex, Inc. is among a select number of biotechnology companies that will make presentations before an international audience of investors, journalists, and biotechnology and pharmaceutical insiders at BIO 2002, the major biotechnology industry trade show taking place in Toronto, June 9th-12th. Vaccinex will be presenting on June 11th at 2:45pm in the Toronto Convention Centre. Vaccinex will, in addition, be participating as an exhibiting company throughout the trade show. Vaccinex was selected from an elite pool of more than 420 applicants to present at the BIO 2002 Business Forum. Companies selected to present at the Business Forum hail from Australia, Austria, Canada, Denmark, Finland, France, Germany, Israel, the Netherlands, Switzerland, the United Kingdom and the United States. Maurice Zauderer, Ph.D., Vaccinex's President and CEO stated, "The participation and visibility of Vaccinex at this premier meeting of the biotechnology industry is a reflection of the progress the company has made in developing exciting new applications for its powerful gene discovery technology. Vaccinex has begun marketing its novel Human Monoclonal Antibody Selection Technology as a service to other biopharmaceutical companies and is, at the same time, preparing for clinical trials of its lead product, a therapeutic vaccine for breast cancer." The 16th Annual BIO 2002 Convention & Exhibition is being held outside the United States for just the second time. More than 15,000 delegates from all over the world will participate in what will be the largest gathering ever for the biotechnology industry. BIO 2002 is sponsored by the Biotechnology Industry Organization (www.BIO.org), which is located in Washington, DC. Headquartered in Rochester, NY, Vaccinex, Inc. is a privately owned biotechnology company developing treatments that harness the power of the body's immune system to fight cancer and other diseases. The company has developed a suite of powerful technologies to identify genes that regulate important biological processes. Vaccinex utilizes the knowledge derived from these technologies in the development of monoclonal antibody-based therapeutics and therapeutic vaccines. For more information, please visit the company's website at www.vaccinex.com. Back to News Archive Copyright © 2008 Vaccinex, Inc.